Open Slide Modal

Inside Ensoma

Ensoma /enˈsōmə/ is derived from the Greek phrase “en soma,” meaning in vivo or in the body.

About Us

At Ensoma, we believe every person, no matter where they are, should have access to innovative technologies that are changing the way we treat disease.


Harnessing the power of our Engenious™ vectors, we can deliver, for the first time, in vivo stem cell and cell-specific modification technologies without the need for prior conditioning, stem cell collection or ex vivo manipulation of cells.

Because our therapies can be delivered in a simple, single injection, we are poised to bring life-changing therapies to people everywhere, including in areas where access to sophisticated healthcare systems or specialty centers may be limited, for a broad array of serious diseases, including rare genetic disorders, immunology and oncology.

Group Image
Group Image
Group Image
Group Image

Our History

Ensoma was established in 2019 by 5AM Ventures and has assembled a highly experienced team with strong operational and gene therapy expertise. Ensoma’s Engenious™ vectors are based on two decades of foundational academic and clinical research generated by our scientific co-founders, Hans-Peter Kiem, M.D., Ph.D. (Fred Hutchinson Cancer Research Center) and André Lieber, M.D., Ph.D. (University of Washington).

Leadership

We have empowered each of our team members to make decisions, overcome obstacles, take risks and — ultimately — achieve what hasn’t been done before.

Paula Soteropoulos

Executive Chairman of the Board

Kush M. Parmar,
M.D., Ph.D.

Chief Executive Officer and Board Member

Robert Peters,
Ph.D.

Chief Scientific Officer

Daniel Leblanc

Chief Technology Officer

Naina Bhasin,
Ph.D.

Chief Business Officer

Patrick Au,
Ph.D.

Vice president, Translational Research and Early Development

John DeSimone

Vice President, Finance

Anthony Forget,
Ph.D.

Vice President, Platform technology

Joe Salas, Ph.D.

Vice president, biology

Soumitra Roy,
M.D., Ph.D.

Distinguished investigator

Betsy Bogard

Head of Program and Alliance Management

Dawn Houlihan

Head of Quality

Chapman Wright,
Ph.D.

Head of Process and Analytical Development


Founders

Hans-Peter Kiem, M.D., Ph.D.


Chief Scientific and Clinical Advisor, Ensoma
Fred Hutchinson Cancer Research Center & University of Washington

André Lieber, M.D., Ph.D.

University of Washington

Board of Directors

Paula Soteropoulos

Executive Chairman of the Board

Albert Seymour,
Ph.D.

Chief Scientific Officer, Homology Medicines

Kush M. Parmar,
M.D., Ph.D.

Chief Executive Officer and Board Member

Stephen Knight,
M.D.

President and Managing Partner, F-Prime CAPTIAL

Scientific Advisory Board

Hans-Peter Kiem,
M.D., Ph.D.

Fred Hutchinson Cancer Research Center & University of Washington

Anja Ehrhardt,
Ph.D.

Universität Witten/Herdecke

Vijay Sankaran,
M.D., Ph.D.

Boston Children’s Hospital

Mark Walters,
M.D.

University of California San Francisco

Investors

Careers

At Ensoma, we are dedicated to making an impact. Join us in our mission to revolutionize medicine for patients who need us.